<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36776391</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>17</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Risk factors and sequelae of epidermolysis bullosa acquisita: A propensity-matched global study in 1,344 patients.</ArticleTitle><Pagination><StartPage>1103533</StartPage><MedlinePgn>1103533</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1103533</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2022.1103533</ELocationID><Abstract><AbstractText>Identification of risk factors and sequelae of any given disease is of key importance. For common diseases, primary prevention and disease management are based on this knowledge. For orphan diseases, identification of risk factors and sequelae has been challenging. With the advent of large databases, e.g., TriNetX, this can now be addressed. We used TriNetX to identify risk factors and sequelae of epidermolysis bullosa acquisita (EBA), a severe and orphan autoimmune disease. To date, there is only enigmatic information on EBA comorbidity. We recruited 1,344 EBA patients in the Global Collaborative Network of TriNetX. Using the "explore outcomes" function we identified 55 diagnoses with a different prevalence between EBA and no-EBA patients. We next performed propensity-matched, retrospective cohort studies in which we determined the risk of EBA development following any of the identified 55 diseases. Here, 31/55 diseases were identified as risk factors for subsequent EBA. Importantly, the highest risk for EBA were other chronic inflammatory diseases (CID), especially lupus erythematosus and lichen planus. Lastly, we determined the risk to develop any of the identified diseases after EBA diagnosis. Here, 38/55 diseases were identified as sequelae. Notably, EBA patients showed an increased risk for metabolic and cardiovascular disease, and thrombosis. Furthermore, the risk for CIDs, especially lupus erythematosus and lichen planus, was elevated. These insights into risk factors and sequelae of EBA are not only of clinical relevance, e.g., optimizing cardiovascular disease risk, but in addition, point to shared pathogenetic pathways between EBA and other inflammatory diseases.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Kridin, Vorobyev, Papara, De Luca, Bieber and Ludwig.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kridin</LastName><ForeName>Khalaf</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>L&#xfc;beck Institute of Experimental Dermatology, University of L&#xfc;beck, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit of Dermatology and Skin Research Laboratory, Barch Padeh Medical Center, Tiberias, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vorobyev</LastName><ForeName>Artem</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Dermatology, University Hospital Schleswig-Holstein L&#xfc;beck, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papara</LastName><ForeName>Cristian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>L&#xfc;beck Institute of Experimental Dermatology, University of L&#xfc;beck, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Luca</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>L&#xfc;beck Institute of Experimental Dermatology, University of L&#xfc;beck, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bieber</LastName><ForeName>Katja</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>L&#xfc;beck Institute of Experimental Dermatology, University of L&#xfc;beck, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ludwig</LastName><ForeName>Ralf J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>L&#xfc;beck Institute of Experimental Dermatology, University of L&#xfc;beck, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Dermatology, University Hospital Schleswig-Holstein L&#xfc;beck, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016107" MajorTopicYN="Y">Epidermolysis Bullosa Acquisita</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="Y">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008010" MajorTopicYN="Y">Lichen Planus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">TriNetX</Keyword><Keyword MajorTopicYN="N">cardiovascular disease</Keyword><Keyword MajorTopicYN="N">epidermolysis bullosa acquisita</Keyword><Keyword MajorTopicYN="N">inflammatory bowel disease</Keyword><Keyword MajorTopicYN="N">lichen planus</Keyword><Keyword MajorTopicYN="N">risk factor</Keyword><Keyword MajorTopicYN="N">sequelae</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus (SLE)</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>13</Day><Hour>3</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36776391</ArticleId><ArticleId IdType="pmc">PMC9910332</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2022.1103533</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sitaru C, Mihai S, Otto C, Chiriac MT, Hausser I, Dotterweich B, et al. . Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen. J Clin Invest (2005) 115:870&#x2013;8. doi:&#xa0;10.1172/JCI21386</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI21386</ArticleId><ArticleId IdType="pmc">PMC1070403</ArticleId><ArticleId IdType="pubmed">15841176</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodley DT, Chang C, Saadat P, Ram R, Liu Z, Chen M. Evidence that anti-type VII collagen antibodies are pathogenic and responsible for the clinical, histological, and immunological features of epidermolysis bullosa acquisita. J Invest Dermatol (2005) 124:958&#x2013;64. doi:&#xa0;10.1111/j.0022-202X.2005.23702.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.0022-202X.2005.23702.x</ArticleId><ArticleId IdType="pubmed">15854036</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram F, Brocker EB, Zillikens D, Schmidt E. Prospective analysis of the incidence of autoimmune bullous disorders in lower franconia, Germany. J Dtsch Dermatol Ges (2009) 7:434&#x2013;40. doi:&#xa0;10.1111/j.1610-0387.2008.06976.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1610-0387.2008.06976.x</ArticleId><ArticleId IdType="pubmed">19170813</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xfc;bner F, Recke A, Zillikens D, Linder R, Schmidt E. Prevalence and age distribution of pemphigus and pemphigoid diseases in Germany. J Invest Dermatol (2016) 136:2495&#x2013;8. doi:&#xa0;10.1016/j.jid.2016.07.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jid.2016.07.013</ArticleId><ArticleId IdType="pubmed">27456755</ArticleId></ArticleIdList></Reference><Reference><Citation>Livden JK, Nilsen R, Thunold S, Schjonsby H. Epidermolysis bullosa acquisita and crohn&#x2019;s disease. Acta Derm Venereol (1978) 58:241&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">78639</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes BR, Horne J. Epidermolysis bullosa acquisita and total ulcerative colitis. J R Soc Med (1988) 81:473&#x2013;5. doi: 10.1177/014107688808100821</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/014107688808100821</ArticleId><ArticleId IdType="pmc">PMC1291723</ArticleId><ArticleId IdType="pubmed">3418663</ArticleId></ArticleIdList></Reference><Reference><Citation>Zumelzu C, Le Roux-Villet C, Loiseau P, Busson M, Heller M, Aucouturier F, et al. . Black patients of African descent and HLA-DRB1*15:03 frequency overrepresented in epidermolysis bullosa acquisita. J Invest Dermatol (2011) 131:2386&#x2013;93. doi:&#xa0;10.1038/jid.2011.231</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jid.2011.231</ArticleId><ArticleId IdType="pubmed">21833018</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw M, McKee PH, Gaminara E, Pearson TC, Evans B, McGibbon DH. Epidermolysis bullosa acquisita associated with chronic lymphatic leukaemia. Clin Exp Dermatol (1985) 10:162&#x2013;8. doi: 10.1111/j.1365-2230.1985.tb00546.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2230.1985.tb00546.x</ArticleId><ArticleId IdType="pubmed">3978864</ArticleId></ArticleIdList></Reference><Reference><Citation>Etienne A, Ruffieux P, Didierjean L, Saurat JH. [Epidermolysis bullosa acquisita and metastatic cancer of the uterine cervix]. Ann Dermatol Venereol (1998) 125:321&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">9747279</ArticleId></ArticleIdList></Reference><Reference><Citation>Endo Y, Tamura A, Ishikawa O, Miyachi Y, Hashimoto T. Psoriasis vulgaris coexistent with epidermolysis bullosa acquisita. Br J Dermatol (1997) 137:783&#x2013;6. doi: 10.1111/j.1365-2133.1997.tb01119.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2133.1997.tb01119.x</ArticleId><ArticleId IdType="pubmed">9415242</ArticleId></ArticleIdList></Reference><Reference><Citation>Aractingi S, Bachmeyer C, Prost C, Caux F, Flageul B, Fermand JP. Subepidermal autoimmune bullous skin diseases associated with b-cell lymphoproliferative disorders. Med (Baltimore) (1999) 78:228&#x2013;35. doi: 10.1097/00005792-199907000-00003</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005792-199907000-00003</ArticleId><ArticleId IdType="pubmed">10424205</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata H, Vorobyev A, Koga H, Recke A, Zillikens D, Prost-Squarcioni C, et al. . Meta-analysis of the clinical and immunopathological characteristics and treatment outcomes in epidermolysis bullosa acquisita patients. Orphanet J Rare Dis (2018) 13:153. doi:&#xa0;10.1186/s13023-018-0896-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13023-018-0896-1</ArticleId><ArticleId IdType="pmc">PMC6122731</ArticleId><ArticleId IdType="pubmed">30180870</ArticleId></ArticleIdList></Reference><Reference><Citation>Elmets CA, Leonardi CL, Davis DMR, Gelfand JM, Lichten J, Mehta NN, et al. . Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol (2019) 80:1073&#x2013;113. doi:&#xa0;10.1016/j.jaad.2018.11.058</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2018.11.058</ArticleId><ArticleId IdType="pubmed">30772097</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. . 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: A report of the American college of Cardiology/American heart association task force on clinical practice guidelines. Circulation (2019) 140:e596&#x2013;646. doi:&#xa0;10.1161/CIR.0000000000000678</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000000678</ArticleId><ArticleId IdType="pmc">PMC7734661</ArticleId><ArticleId IdType="pubmed">30879355</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et al. . Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet (2016) 388:2532&#x2013;61. doi:&#xa0;10.1016/S0140-6736(16)31357-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(16)31357-5</ArticleId><ArticleId IdType="pubmed">27616593</ArticleId></ArticleIdList></Reference><Reference><Citation>Gwinnutt JM, Wieczorek M, Balanescu A, Bischoff-Ferrari HA, Boonen A, Cavalli G, et al. . EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases. Ann Rheum; (2023) 82(1):48&#x2013;56. doi:&#xa0;10.1136/annrheumdis-2021-222020</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-222020</ArticleId><ArticleId IdType="pubmed">35260387</ArticleId></ArticleIdList></Reference><Reference><Citation>Pegum JS, Wright JT. Epidermolysis bullosa acquisita and crohn&#x2019;s disease. Proc R Soc Med (1973) 66:234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1644810</ArticleId><ArticleId IdType="pubmed">4697982</ArticleId></ArticleIdList></Reference><Reference><Citation>Raab B, Fretzin DF, Bronson DM, Scott MJ, Roenigk HHJ, Medenica M. Epidermolysis bullosa acquisita and inflammatory bowel disease. JAMA (1983) 250:1746&#x2013;8. doi: 10.1001/jama.1983.03340130064034</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1983.03340130064034</ArticleId><ArticleId IdType="pubmed">6887488</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy H, Shipman AR, Wojnarowska F. Epidermolysis bullosa acquisita and inflammatory bowel disease: a review of the literature. Clin Exp Dermatol (2013) 38:225&#x2013;30. doi:&#xa0;10.1111/ced.12114</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ced.12114</ArticleId><ArticleId IdType="pubmed">23517353</ArticleId></ArticleIdList></Reference><Reference><Citation>Koga H, Prost-Squarcioni C, Iwata H, Jonkman MF, Ludwig RJ, Bieber K. Epidermolysis bullosa acquisita: The 2019 update. Front Med (Lausanne) (2019) 5:362. doi:&#xa0;10.3389/fmed.2018.00362</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2018.00362</ArticleId><ArticleId IdType="pmc">PMC6335340</ArticleId><ArticleId IdType="pubmed">30687710</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JH, Kim YH, Kim SC. Epidermolysis bullosa acquisita: A retrospective clinical analysis of 30 cases. Acta Derm Venereol (2011) 91:307&#x2013;12. doi:&#xa0;10.2340/00015555-1065</Citation><ArticleIdList><ArticleId IdType="doi">10.2340/00015555-1065</ArticleId><ArticleId IdType="pubmed">21394418</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xfc;rcan HM, Ahmed AR. Current concepts in the treatment of epidermolysis bullosa acquisita. Expert Opin Pharmacother (2011) 12:1259&#x2013;68. doi:&#xa0;10.1517/14656566.2011.549127</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14656566.2011.549127</ArticleId><ArticleId IdType="pubmed">21254861</ArticleId></ArticleIdList></Reference><Reference><Citation>Korman NJ. Management of psoriasis as a systemic disease: what is the evidence. Br J Dermatol (2020) 182:840&#x2013;8. doi:&#xa0;10.1111/bjd.18245</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjd.18245</ArticleId><ArticleId IdType="pmc">PMC7187293</ArticleId><ArticleId IdType="pubmed">31225638</ArticleId></ArticleIdList></Reference><Reference><Citation>Amin M, Lee EB, Tsai TF, Wu JJ. Psoriasis and Co-morbidity. Acta Derm Venereol (2020) adv00033. doi:&#xa0;10.2340/00015555-3387</Citation><ArticleIdList><ArticleId IdType="doi">10.2340/00015555-3387</ArticleId><ArticleId IdType="pmc">PMC9128942</ArticleId><ArticleId IdType="pubmed">31971602</ArticleId></ArticleIdList></Reference><Reference><Citation>Restivo V, Candiloro S, Daidone M, Norrito R, Cataldi M, Minutolo G, et al. . Systematic review and meta-analysis of cardiovascular risk in rheumatological disease: Symptomatic and non-symptomatic events in rheumatoid arthritis and systemic lupus erythematosus. Autoimmun Rev (2022) 21:102925. doi:&#xa0;10.1016/j.autrev.2021.102925</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.102925</ArticleId><ArticleId IdType="pubmed">34454117</ArticleId></ArticleIdList></Reference><Reference><Citation>Bieber K, Harder M, St&#xe4;nder S, Boch K, Kridin K, K&#xf6;hler B, et al. . DNA Chip-based diagnosis of onychomycosis and tinea pedis. J Dtsch Dermatol Ges (2022) 20:1112&#x2013;21. doi:&#xa0;10.1111/ddg.14819</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ddg.14819</ArticleId><ArticleId IdType="pubmed">35853241</ArticleId></ArticleIdList></Reference><Reference><Citation>Witte M, Zillikens D, Schmidt E. Diagnosis of autoimmune blistering diseases. Front Med (Lausanne) (2018) 5:296. doi:&#xa0;10.3389/fmed.2018.00296</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2018.00296</ArticleId><ArticleId IdType="pmc">PMC6224342</ArticleId><ArticleId IdType="pubmed">30450358</ArticleId></ArticleIdList></Reference><Reference><Citation>Garshick MS, Ward NL, Krueger JG, Berger JS. Cardiovascular risk in patients with psoriasis: JACC review topic of the week. J Am Coll Cardiol (2021) 77:1670&#x2013;80. doi:&#xa0;10.1016/j.jacc.2021.02.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2021.02.009</ArticleId><ArticleId IdType="pmc">PMC8168628</ArticleId><ArticleId IdType="pubmed">33795041</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT. Update on the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis (2021) 80:14&#x2013;25. doi:&#xa0;10.1136/annrheumdis-2020-218272</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-218272</ArticleId><ArticleId IdType="pubmed">33051219</ArticleId></ArticleIdList></Reference><Reference><Citation>Figus FA, Piga M, Azzolin I, McConnell R, Iagnocco A. Rheumatoid arthritis: Extra-articular manifestations and comorbidities. Autoimmun Rev (2021) 20:102776. doi:&#xa0;10.1016/j.autrev.2021.102776</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.102776</ArticleId><ArticleId IdType="pubmed">33609792</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramagopalan SV, Wotton CJ, Handel AE, Yeates D, Goldacre MJ. Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study. BMC Med (2011) 9:1. doi:&#xa0;10.1186/1741-7015-9-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1741-7015-9-1</ArticleId><ArticleId IdType="pmc">PMC3025873</ArticleId><ArticleId IdType="pubmed">21219637</ArticleId></ArticleIdList></Reference><Reference><Citation>Marzano AV, Tedeschi A, Polloni I, Crosti C, Cugno M. Prothrombotic state and impaired fibrinolysis in bullous pemphigoid, the most frequent autoimmune blistering disease. Clin Exp Immunol (2013) 171:76&#x2013;81. doi:&#xa0;10.1111/j.1365-2249.2012.04674.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2249.2012.04674.x</ArticleId><ArticleId IdType="pmc">PMC3530098</ArticleId><ArticleId IdType="pubmed">23199326</ArticleId></ArticleIdList></Reference><Reference><Citation>Boh E, Roberts LJ, Lieu TS, Gammon WR, Sontheimer RD. Epidermolysis bullosa acquisita preceding the development of systemic lupus erythematosus. 2319019 (1990) 22:587&#x2013;93. doi: 10.1016/0190-9622(90)70077-U</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0190-9622(90)70077-U</ArticleId><ArticleId IdType="pubmed">2319019</ArticleId></ArticleIdList></Reference><Reference><Citation>McHenry PM, Dagg JH, Tidman MJ, Lever RS. Epidermolysis bullosa acquisita occurring in association with systemic lupus erythematosus. Clin Exp Dermatol (1993) 18:378&#x2013;80. doi: 10.1111/j.1365-2230.1993.tb02224.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2230.1993.tb02224.x</ArticleId><ArticleId IdType="pubmed">8403483</ArticleId></ArticleIdList></Reference><Reference><Citation>Contestable JJ, Edhegard KD, Meyerle JH. Bullous systemic lupus erythematosus: a review and update to diagnosis and treatment. Am J Clin Dermatol (2014) 15:517&#x2013;24. doi:&#xa0;10.1007/s40257-014-0098-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40257-014-0098-0</ArticleId><ArticleId IdType="pubmed">25358414</ArticleId></ArticleIdList></Reference><Reference><Citation>Buijsrogge JJ, Diercks GF, Pas HH, Jonkman MF. The many faces of epidermolysis bullosa acquisita after serration pattern analysis by direct immunofluorescence microscopy. Br J Dermatol (2011) 165:92&#x2013;8. doi:&#xa0;10.1111/j.1365-2133.2011.10346.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2133.2011.10346.x</ArticleId><ArticleId IdType="pubmed">21457208</ArticleId></ArticleIdList></Reference><Reference><Citation>Licarete E, Ganz S, Recknagel M, Di Zenzo G, Hashimoto T, Hertl M, et al. . Prevalence of collagen VII-specific autoantibodies in patients with autoimmune and inflammatory diseases. BMC Immunol (2012) 13:16. doi:&#xa0;10.1186/1471-2172-13-16</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2172-13-16</ArticleId><ArticleId IdType="pmc">PMC3368718</ArticleId><ArticleId IdType="pubmed">22471736</ArticleId></ArticleIdList></Reference><Reference><Citation>Luke MC, Darling TN, Hsu R, Summers RM, Smith JA, Solomon BI, et al. . Mucosal morbidity in patients with epidermolysis bullosa acquisita. Arch Dermatol (1999) 135:954&#x2013;9. doi: 10.1001/archderm.135.8.954</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archderm.135.8.954</ArticleId><ArticleId IdType="pubmed">10456345</ArticleId></ArticleIdList></Reference><Reference><Citation>Hundt JE, Iwata H, Pieper M, Pf&#xfc;ndl R, Bieber K, Zillikens D, et al. . Visualization of autoantibodies and neutrophils in vivo identifies novel checkpoints in autoantibody-induced tissue injury. Sci Rep (2020) 10:4509. doi:&#xa0;10.1038/s41598-020-60233-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-60233-w</ArticleId><ArticleId IdType="pmc">PMC7066238</ArticleId><ArticleId IdType="pubmed">32161277</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishii N, Recke A, Mihai S, Hirose M, Hashimoto T, Zillikens D, et al. . Autoantibody-induced intestinal inflammation and weight loss in experimental epidermolysis bullosa acquisita. J Pathol (2011) 224:234&#x2013;44. doi: 10.1002/path.2857</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.2857</ArticleId><ArticleId IdType="pubmed">21381035</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>